Search

Your search keyword '"Kamenicky, Peter"' showing total 248 results

Search Constraints

Start Over You searched for: Author "Kamenicky, Peter" Remove constraint Author: "Kamenicky, Peter"
248 results on '"Kamenicky, Peter"'

Search Results

4. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.

6. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP)

7. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study

9. Results of systematic KDM1A genotyping in a large series of Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH) patients and analysis of the genotype/phenotype correlation

11. Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome

12. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study

14. Hypertension in Acromegaly

20. Adult Height Improved Over Decades in Patients with X-Linked Hypophosphatemia: a cohort study

21. OR17-05 Lysine Demethylase KDM1A And Ectopic Expression Of GIP-Receptor In Somatotropinomas Of Patients With Paradoxical Response To Oral Glucose

23. SAT237 AZP-3601, A Novel PTH 1 Receptor Agonist, Induces Rapid Reduction And Normalization Of Urinary Calcium In Chronic Hypoparathyroid Patients

24. THU059 Increased Intracellular And Extracellular Myocardial Masses On Cardiac Magnetic Resonance Imaging In Patents With Acromegaly

25. FRI163 Central Role Of Mirnas During Kidney Development And Establishment Of The Mineralocorticoid Signaling Pathway Establishment Of The Mineralocorticoid Signaling Pathway

26. OR23-04 Treatment Of Chronic Hypoparathyroidism With Eneboparatide (AZP-3601), A Novel PTH 1 Receptor Agonist: Results From A Phase 2 Trial

28. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

29. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

30. Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion

31. Eneboparatide, a novel PTH 1 receptor agonist, induces rapid reduction and normalization of urinary calcium in chronic hypoparathyroid patients

32. Lysine demethylase KDM1A and ectopic expression of GIP-receptor in somatotropinomas of patients with paradoxical response to oral glucose

33. Treatment of chronic hypoparathyroidism by Eneboparatide, a novel PTH receptor-1 agonist: Results from a phase 2a study

34. Description of 38 novel ARMC5 variants and review of the literature: the updated mutational landscape of ARMC5 in Bilateral Macronodular Adrenocortical Disease

35. Increased intracellular and extracellular myocardial mass on cardiac magnetic resonance imaging in patients with acromegaly

38. Impact of Cushing's syndrome on the gonadotrope axis and testicular functions in men.

40. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment

41. Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion

44. Germline loss-of-functionPAMvariants are enriched in subjects with pituitary hypersecretion

45. Combining metabolomics and machine learning models as a tool to distinguish non-classic 21-hydroxylase deficiency from polycystic ovary syndrome without adrenocorticotropic hormone testing

46. Genotype-phenotype Description of Vitamin D–dependent Rickets 1A: CYP27B1 p.(Ala129Thr) Variant Induces a Milder Disease

47. OR12-3 Identification of Predictive Criteria for the Primary Bilateral Macronodular Adrenal Hyperplasia Gene ARMC5: A European Series of 352 Unselected Patients.

48. RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection

49. OR04-4 Loss of KDM1A in Bilateral Macronodular Adrenal Hyperplasia With GIP-Dependent Cushing's Syndrome and in Acromegaly With Paradoxical GH Response to Oral Glucose

50. Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients

Catalog

Books, media, physical & digital resources